Home ›
Breast Cancer Trials ›
NCT07895511
A Study of Skipping Radiation Therapy in People With Breast Cancer
The purpose of this study is to find out whether it is safe to skip (omit) radiation therapy to the breast after lumpectomy in people with low-risk HER2-positive breast cancer who are receiving HER2-targeted therapy.
Trial Details
NCT ID NCT07895511
Phase NA
Sponsor Memorial Sloan Kettering Cancer Center
Status RECRUITING
Cancer Type Breast Cancer
Interventions HER2-targeted therapy Tamoxifen No Radiation Therapy
Locations (sample) Basking Ridge, New Jersey, United States|40.70621,-74.54932 Middletown, New Jersey, United States|40.39428,-74.11709 Montvale, New Jersey, United States|41.04676,-74.02292 Commack, New York, United States|40.84288,-73.29289 Harrison, New York, United States|40.96899,-73.71263
Key Eligibility Criteria
A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Please contact the study PI for exceptions, … The trial is open to female and male patients who have undergone breast conserving surgery and have received neoadjuvant\* or adjuvant systemic the… The maximum window between surgery (neoadjuvant cohort) or last chemotherapy (adjuvant cohort) and enrollment is 90 days. While the standard duration of neoadjuvant or adjuvant systemic therapy is at least 12 weeks, patients will be eligible if they receive a minimum o…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →